Can a Two-Drug combo outsmart advanced liver cancer?

NCT ID NCT06487559

NEW Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a specific type of liver cancer (Child-Pugh A) who have already received an immune checkpoint inhibitor. Participants receive the drugs by intravenous infusion every three weeks, and researchers will monitor side effects, how the drugs move through the body, and any signs of tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Livmoniplimab (ABBV-151) combined with budigalimab (ABBV-181), both given as intravenous infusions
What this could lead to: If successful, this combination could offer a new treatment option for advanced liver cancer patients who have not responded to standard first-line therapy.
What could go wrong: This is an early-phase study with a small number of participants, so results may not apply broadly. The drugs may cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928

Beijing, Beijing Municipality, 100069, China
Harbin Medical University Cancer Hospital /Id# 262070

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital /ID# 262098

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital /ID# 262030

Wuhan, Hubei, 430079, China
Liaoning Cancer Hospital & Institute /ID# 268023

Shenyang, Liaoning, 110042, China
Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443

Fuzhou, Fujian, 350012, China
Nanfang Hospital of Southern Medical University /ID# 262091

Guangzhou, Guangdong, 510515, China
Sun Yat-Sen University Cancer Center /ID# 262092

Guangzhou, Guangdong, 510060, China
The Second Affiliated Hospital of Nanchang University /ID# 262085

Nanchang, Jiangxi, 330008, China
Zhejiang Cancer hospital /ID# 262046

Hangzhou, Zhejiang, 310022, China
Zhongshan Hospital Fudan University /ID# 262135

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.